Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06702007 · ClinicalTrials.gov registry record · Phase 3
Electronic Harm Reduction Treatment for Alcohol
A Phase 3 study of Alcohol Use Disorder and Harm Reduction, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT06702007: Recruiting Phase 3 study of Alcohol Use Disorder and Harm Reduction, sponsored by University of Washington.
NCT06702007 is a Phase 3 study of Alcohol Use Disorder and Harm Reduction that is actively recruiting participants, run by University of Washington. The registered enrollment target is 160 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06702007, a Phase 3 study of Alcohol Use Disorder and Harm Reduction, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this project is to transform a successful, face-to-face harm-reduction treatment (HaRT-A) into a digital format, creating eHaRT-A. This new platform is specifically designed for people who have experienced homelessness and an alcohol use disorder (AUD), living within the framework of permanent, supportive, Housing First (HF) facilities. We hypothesize eHaRT-A will be more effective than the standard HF services in reducing alcohol-related harm and improving the overall quality of life for participants.
Primary Outcome
The EQ-5D-5L is a psychometrically sound, 5-item, 5-point Likert scale measure that comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Its summary score will reflect participants' health-related quality of life (HRQoL) as a primary outcome.
Conditions Studied
Interventions
- BEHAVIORAL eHaRT-A
Study Locations (1)
Washington
- Downtown Emergency Service Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-01-20 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 3 |
What NCT06702007 shows while recruiting
NCT06702007 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (51% lower).
The record links to 3 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which eHaRT-A is the first listed.
NCT06702007 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06702007 about?
NCT06702007 is a clinical study titled "Electronic Harm Reduction Treatment for Alcohol". The goal of this project is to transform a successful, face-to-face harm-reduction treatment (HaRT-A) into a digital format, creating eHaRT-A. This new platform is specifically designed for people who have experienced homelessness and an alcohol use disorder (AUD), living within the framework of per...
What is the current status of trial NCT06702007?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2025-01-20. Estimated completion is 2027-08-31.
What conditions does trial NCT06702007 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Harm Reduction, Housing First (eg. Permanent Supportive Housing).
What interventions are being tested in trial NCT06702007?
The interventions under investigation include: eHaRT-A (BEHAVIORAL).
Who is sponsoring clinical trial NCT06702007?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06702007 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06702007's enrollment target sits among peer trials
160 58th of 184 higher than 125 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Brenipatide in Participants With Alcohol Use Disorder
RECRUITING · Phase 3
-
Emergency Department-Initiated Medications for Alcohol Use Disorder
RECRUITING · Phase 3
-
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
RECRUITING · Phase 3
-
Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action
COMPLETED · Phase 3
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI